Biocon Limited (BSE:532523) (NSE:BIOCON), an India-based global biopharmaceutical company, announced on Wednesday the inauguration of its first US manufacturing facility in Cranbury, New Jersey, by its wholly owned subsidiary, Biocon Generics Inc (BGI).

The Governor of New Jersey, Phil Murphy, was guest of honour at the inauguration. Biocon's chairperson, Kiran Mazumdar-Shaw, and a gathering of dignitaries, customers, partners, and industry leaders were in attendance.

Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc in 2023 and has since invested over USD30m to establish a plant with an annual production capacity of 2 billion tablets. The company says that a few products have already been commercialised from the site, with several more in the pipeline. This investment is intended to help Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint.

According to Biocon, the Cranbury facility represents a strategic advancement for its US operations, enabling faster access to essential therapies, enhanced supply reliability and a stronger connection with partners and healthcare providers, ultimately benefitting patients across the United States.